IL23A and Alzheimer disease: On the basis of current knowledge, introducing the TH17 efficacy as a potent inflammatory lineage, targeting IL-23/TH17 axis, may be a promising approach that paves the way for additive and alternative treatment of chronic inflammation and AD [75].